Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: Long-term quantitative molecular remission in relapsed P-190BCR-ABL positive acute lymphoblastic leukemia [1]

Leukemia

Volumn 16, Issue 10, 2002, Pages 2159-2160

  Visani, G ^a   Isidori, A ^b   Malagola, M ^b   Alberti, D ^c   Capdeville, R ^d   Martinelli, G ^b   Piccaluga, P P ^b   Amabile, M ^b   Guiducci, B ^a   Tura, S ^b   Baccarani, M ^b  

^a H San Salvatore ^*  (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Novartis Pharma   (Italy)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; HYBRID PROTEIN; IMATINIB; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; ROFERON ALPHA; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; LEUKEMIA REMISSION; MAINTENANCE THERAPY; NAUSEA; PRIORITY JOURNAL; VOMITING;

EID: 0036798736     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402729     Document Type: Letter

References (7)

1. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
3. BCR-ABL positive adult acute lymphoblastic leukemia. Leukemia 2000; 14: 22-27.
4. Amabile M, Giannini B, Testoni N, Montefusco V, Rosti GA, Zardini C, Terragna C, Buonamici S, Ottaviani E, Soverini 5, Fiacchini M, Bassi S, De Vivo A, Trabacchi E. Saglio G, Pane F, Baccarani M, Tura S, Martinelli G. Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. Haematologica 2001; 86: 252-259.
5. Buchdunger E, Zimmerman J, Mett H, Meyer T, Muller M, Druker BJ, Zimmerman J, Lydon NB. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-104.
6. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmerman J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
7. Thiesing JT, Ohno-Jones 5, Kolibaba KS, Druker BJ. Efficacy of ST1571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells. Blood 2000; 96: 3195-3199.